CAR-T cells targeting CD38 and LMP1 exhibit robust antitumour activity against NK/T cell lymphoma

CAR-T cells targeting CD38 and LMP1 exhibit robust antitumour activity against NK/T cell lymphoma

Abstract Background Natural killer/T cell lymphoma (NKTCL) is an aggressive lymphoma with a poor prognosis. Chimeric antigen receptor-transduced T (CAR-T) cell therapy has become a promising immunotherapeutic strategy against haematologic malignancies. Methods In this study, four CAR-T cell lines (C...

Full description

Bibliographic Details
Main Authors: Hongwen Li, Wenting Song, Jiazhuo Wu, Zhuangzhuang Shi, Yuyang Gao, Jiwei Li, Lijuan Han, Jianxiang Zhang, Zhaoming Li, Yong Li, Mingzhi Zhang
Format: Article
Language:English
Published: BMC 2023-08-01
Series:BMC Medicine
Subjects:
CD38
LMP1
CAR-T
Tandem
Immunotherapy
NKTCL
Online Access:https://doi.org/10.1186/s12916-023-03040-0

Internet

https://doi.org/10.1186/s12916-023-03040-0

Similar Items